Vertex Pharmaceuticals Incorporated (Vertex) is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Telaprevir, the Company’s principal drug candidate, is an oral hepatitis C protease inhibitor and an antiviral treatment in clinical development that targets hepatitis C virus (HCV) infection. As of December 31, 2008, Vertex was also developing, among other compounds, VX-770, a drug candidate for the treatment of patients with cystic fibrosis (CF). In March 2009, the Company completed its acquisition of ViroChem Pharma Inc., a company with two investigational HCV polymerase inhibitors in clinical development.